The table above uses one worked example. These are the published quantities, converted into marks on a U-100 barrel at each water volume for a 10 mg vial. Where a quantity was never studied by injection, the row says so.
4–6 mg — studied in a trial
4–6 mg once weekly, stepped up from 2 mg in four-week stages, under the skin.
4–6 mg once weekly for 24 weeks against placebo, then 24 weeks of open treatment, under the skin. A separate trial ran the same doses against dulaglutide.
| Water added | Concentration | Draw, low to high |
|---|
| 1 mL | 10.00 mg/mL | 40.0 to 60.0 units |
| 2 mL | 5.00 mg/mL | 80.0 to 120.0 unitswon’t fit |
Human trialJi L et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med 2025;392:2215-2225 (GLORY-1, NCT05607680, PMID 40421736) · retrieved 2026-08-17
Human trialZhu D, Zhao J et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature 2026;652:174-180 — a 24-week phase 3 trial of 4 mg and 6 mg weekly, followed by 24 weeks of open treatment (PMID 41407859) · retrieved 2026-08-17
9 mg — studied in a trial
9 mg once weekly for 60 weeks, the single arm of a second phase 3 trial, reached by a gradual climb the report does not detail, under the skin.
| Water added | Concentration | Draw |
|---|
| 1 mL | 10.00 mg/mL | 90.0 units |
| 2 mL | 5.00 mg/mL | 180.0 unitswon’t fit |
Human trialGao L et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA 2026;336(5):377-388 — 60 weeks, ClinicalTrials.gov NCT06164873 (PMID 42251595) · retrieved 2026-08-17
3–6 mg — studied in a trial
3–6 mg once weekly for 24 weeks across three arms, in the dose-finding trial that chose the doses every later trial used, under the skin.
| Water added | Concentration | Draw, low to high |
|---|
| 1 mL | 10.00 mg/mL | 30.0 to 60.0 units |
| 2 mL | 5.00 mg/mL | 60.0 to 120.0 unitswon’t fit |
Human trialJi L, Jiang H et al. A phase 2 randomized controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun 2023;14:8289 — 248 participants across 3 mg, 4.5 mg and 6 mg arms over 24 weeks, ClinicalTrials.gov NCT04904913 (PMID 38092790) · retrieved 2026-08-17
9–10 mg — studied in a trial
9–10 mg once weekly in four-week stages: 3 then 6 then 9 mg over twelve weeks, or 2.5 then 5 then 7.5 then 10 mg over sixteen, under the skin.
| Water added | Concentration | Draw, low to high |
|---|
| 1 mL | 10.00 mg/mL | 90.0 to 100.0 units |
| 2 mL | 5.00 mg/mL | 180.0 to 200.0 unitswon’t fit |
Human trialJi L, Gao L et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine 2022;54:101691 (PMID 36247927) · retrieved 2026-08-17